Artios Pharma
CompanyUnited Kingdom
Artios Pharma develops 3 assets, the furthest in phase 2 (Alnodesertib). Mostly small molecule and antibody acting on DNA damage response, DNA repair and ATR; based in the United Kingdom.
- 3
- Assets
- Furthest stage
- Phase 2
- Raised
- US$199m
- 0
- Trials
- 0
- Signals
Pipeline
3Inhibits ATR signaling, causing replication fork collapse, DNA double-strand breaks, and cancer cell death.
Phase 2, Small molecule, DNA damage response, DNA repair, solid tumour (Phase 1)
Inhibits DNA polymerase theta, impairing DNA repair and enhancing cancer cell killing in combination with PARP inhibitors.
Phase 2, Small molecule, DNA damage response, DNA repair, breast cancer (Phase 1), solid tumour (Phase 1)
Targets TROP2 and delivers a payload that locks PARP onto chromatin, causing DNA double-strand breaks and cell death.
Preclinical, Antibody
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Funding rounds and grants2
- People14
- Signals1
- Similar companies6